Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May 29;14(11):3821.
doi: 10.3390/jcm14113821.

The Role of Global Physical Capacity Score in Key Parameters of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Affiliations

The Role of Global Physical Capacity Score in Key Parameters of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Nicola Verrelli et al. J Clin Med. .

Abstract

Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is linked to metabolic syndrome, type 2 diabetes, and obesity. This study investigates the relationship between physical capacity, assessed by the Global Physical Capacity Score (GPCS), and MASLD-related parameters, including hepatic steatosis (CAP score), insulin resistance (HOMA-IR), and body mass index (BMI). Methods: A cross-sectional analysis was performed on 204 individuals with MASLD (mean age: 50 years; 57.6% males). Participants underwent physical tests to determine their GPCS. Hepatic steatosis was assessed using FibroScan® (Echosens, Paris, France), and metabolic markers were collected from fasting blood samples. Statistical analyses included linear and logistic regression models adjusted for potential confounders. Results: A higher GPCS was inversely associated with CAP (β = -5.30; p < 0.05), HOMA-IR (β = -0.28; p < 0.001), and BMI (β = -0.96; p < 0.001). Logistic regression analysis confirmed a lower risk of severe hepatic steatosis (OR = 0.44; p < 0.05), obesity (OR = 0.39; p < 0.05), and insulin resistance (OR = 0.32; p < 0.001) in individuals with higher GPCS values. Conclusions: The GPCS may indicate MASLD severity and reflect metabolic and hepatic health. Our findings support the promotion of physical activity and suggest a potential role for GPCS in risk stratification and personalized interventions for patients with MASLD.

Keywords: Global Physical Capacity Score; HOMA-IR; body mass index; hepatic steatosis; metabolic-associated steatotic liver disease; physical activity.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Flow chart of studies and participants. OB_AF: Obesity_ AF Study; M: Males; F: Females; GPCS: Global Physical Capacity Score.
Figure 2
Figure 2
Plot (a): Predictive margins with 95% CI for BMI from a linear regression of BMI on GPCS. Plot (b): Predictive margins with 95% CI for CAP from a linear regression of CAP on GPCS. Plot (c): Predictive margins with 95% CI of the prediction for HOMA-IR from a linear regression of HOMA-IR on GPCS. Model regression adjusted for gender (F 0, M1), age, marital status, HbA1, and cortisol. The dashed line indicates the median value of GPCS.

References

    1. Calzadilla-Bertot L., Jeffrey G.P., Wang Z., Huang Y., Garas G., Wallace M., De Boer B., George J., Eslam M., Phu A., et al. Predicting Liver-Related Events in NAFLD: A Predictive Model. Hepatology. 2023;78:1240–1251. doi: 10.1097/HEP.0000000000000356. - DOI - PubMed
    1. Kim G.-A., Moon J.H., Kim W. Critical Appraisal of Metabolic Dysfunction-Associated Steatotic Liver Disease: Implication of Janus-Faced Modernity. Clin. Mol. Hepatol. 2023;29:831–843. doi: 10.3350/cmh.2023.0277. - DOI - PMC - PubMed
    1. Kim D., Danpanichkul P., Wijarnpreecha K., Cholankeril G., Loomba R., Ahmed A. Current Burden of Steatotic Liver Disease and Fibrosis among Adults in the United States, 2017–2023. Clin. Mol. Hepatol. 2025;31:382–393. doi: 10.3350/cmh.2024.0987. - DOI - PMC - PubMed
    1. Younossi Z.M., AlQahtani S.A., Funuyet-Salas J., Romero-Gómez M., Yilmaz Y., Keklikkiran C., Alswat K., Yu M.-L., Liu C.-J., Fan J.-G., et al. The Impact of Stigma on Quality of Life and Liver Disease Burden among Patients with Nonalcoholic Fatty Liver Disease. JHEP Rep. 2024;6:101066. doi: 10.1016/j.jhepr.2024.101066. - DOI - PMC - PubMed
    1. Yoon E.L., Jun D.W. Waiting for the Changes after the Adoption of Steatotic Liver Disease. Clin. Mol. Hepatol. 2023;29:844–850. doi: 10.3350/cmh.2023.0291. - DOI - PMC - PubMed

LinkOut - more resources